Academic Journal
Safety and effectiveness of CIMAvax-EGF administered in community polyclinics.
| Title: | Safety and effectiveness of CIMAvax-EGF administered in community polyclinics. |
|---|---|
| Authors: | Ortiz Carrodeguas, Ramón A., Lorenzo Monteagudo, Geidy, Guerra Chaviano, Pedro P., Álvarez Montané, Irene, Salomón Saldívar, Eva E., Lambert, Leonardo Lobaina, Kirenia Camacho Sosa, Bermúdez Pino, Raúl, Blanco Mustelier, Poncio, Valdés Rodríguez, Elba, González Piloto, Shairis, Guerra de la Vega, Arelys, Valdés Sánchez, Lizet, Montes De Santis, Arasay, Parra Zabala, Jenelly, Viada González, Carmen, Calvo Aguilera, Nadia, Saavedra Hernández, Danay, Santos Morales, Orestes, Crombet Ramos, Tania |
| Source: | Frontiers in Oncology; 2024, p1-10, 10p |
| Abstract: | In spite of the advances in immunotherapy and targeted therapies, lung cancer continues to be the leading cause of cancer-related death. The epidermal growth factor receptor is an established target for non-small cell lung cancer (NSCLC), and its overactivation by the ligands can induce accelerated proliferation, angiogenesis, and metastasis as well as proinflammatory or immunosuppressive signals. CIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy that is approved for the treatment of NSCLC patients in Cuba. The study was designed as a phase IV trial to characterize the safety and effectiveness of CIMAvax-EGF in advanced NSCLC patients treated in 119 community polyclinics and 24 hospitals. CIMAvax-EGF treatment consisted of four bi-weekly doses followed by monthly boosters. Overall, 741 NSCLC patients ineligible for further cancer-specific treatment were enrolled. CIMAvax-EGF was safe, and the most common adverse events consisted of mild-to-moderate injection site reactions, fever, chills, tremors, and headache. For patients completing the loading doses, the median survival was 9.9 months. For individuals achieving at least stable disease to the frontline and completing vaccination induction, the median survival was 12 months. Most of the functional activities and symptoms evaluated through the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire improved over time. In conclusion, this real-world trial demonstrated that CIMAvax-EGF was safe and effective in patients who were vaccinated in the maintenance scenario. A larger effect was seen in subjects with poor prognosis like those with squamous tumors and high EGF levels. Remarkably, this community-based intervention was very important because it demonstrated the feasibility of treating advanced lung cancer patients with active immunotherapy in primary care institutions. In addition to CIMAvax-EGF, patients received supportive care at the community clinic. Vaccine administration by the family doctors at the polyclinics reduced the patients' burden on the medical oncology services that continued providing chemotherapy and other complex therapies. We conclude that community polyclinics constitute the optimal scenario for administering those cancer vaccines that are safe and require prolonged maintenance in patients with advanced cancer, despite the continuous deterioration of their general condition. [ABSTRACT FROM AUTHOR] |
| Copyright of Frontiers in Oncology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| ISSN: | 2234943X |
| DOI: | 10.3389/fonc.2023.1287902 |
| Database: | Complementary Index |
Availability